Skip to content

Nizatidine

    Brands

    DEA Class; Rx

    Common Brand Names; Axid

    • Histamine H2 Antagonists

    Oral histamine type 2-receptor antagonist
    Used for gastroesophageal reflux disease (GERD), short-term and maintenance treatment of duodenal ulcer, and short-term treatment of active benign gastric ulcer
    For GERD, proton pump inhibitors (PPIs) are considered to be more effective than H2-blockers

    Indicated for 

    • Active Duodenal Ulcer
    • Duodenal Ulcer Maintenance
    • Benign Gastric Ulcer
    • GERD

    Hypersensitivity to nizatidine or other H2 receptor antagonists

    • Headache (17%)
    • Abdominal pain
    • Anxiety
    • Constipation
    • Diarrhea
    • Dizziness
    • Insomnia
    • Nausea/vomiting
    • Pruritus

    Before taking the medication ask a healthcare professional if experiencing pain when swallowing food, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds, heartburn that has lasted for longer than 3 months, heartburn that causes wheezing or feeling like passing out, unusual weight loss, stomach pain, nausea, or vomiting, frequent chest pain, kidney disease, or liver disease

    Heartburn is often confused with first symptoms of a heart attack; seek emergency medical attention if experiencing chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling

    If patient taking a prescription drug, the patient should ask a doctor or a pharmacist whether acid reducers can be taken concomitantly with it

    Prolonged therapy may lead to vitamin B12 malabsorption and subsequently, deficiency

    Relief of symptoms does not preclude absence of malignancy

    Increased risk for development of acute gastroenteritis and community acquired pneumonia associated reported in pediatric patients

    May see false positive urobilinogen secondary to nizatidine

    There are no adequate and well-controlled studies in pregnant women

    Studies conducted in lactating women showed that 0.1% of orally administered nizatidine is secreted in human milk in proportion to plasma concentrations

    Adults

    300 mg/day PO.

    Geriatric

    300 mg/day PO.

    Adolescents

    300 mg/day PO.

    Children

    12 years and older: 300 mg/day PO.
    1 to 11 years: 10 to 20 mg/kg/day PO has been studied.

    Infants

    6 months and older: 10 to 20 mg/kg/day PO has been studied.
    1 to 5 months: 10 mg/kg/day PO has been studied.

    Neonates

    10 mg/kg/day PO has been studied.

    Nizatidine

    capsule

    • 150mg
    • 300mg

    oral solution

    • 15mg/mL

    tablet

    • 75mg